The Indian market is expected to trade higher. Here is a list of top fifteen stocks that are likely to be in focus today.

Drug firm Sanofi India has sold its commercial property, land along with a building known as 'Aventis House' in Mumbai, for Rs 111 crore.

The company, which follows January-December financial year, had posted a net profit of Rs 57.5 crore in the corresponding period of the pre...

Mallya, however, continues to strike a defiant note and has refused to step down while taking refuse in "certain contractual obligations".

According to advisory firm, Grant Thornton, corporates in the country announced 458 deals in January-November period.

French multinational pharmaceutical company Sanofi's Indian subsidiary has acquired 150,000 sq ft of office space at its new project in Pow...

Majority of Indian pharmaceutical companies fear pressure on profit margins by at least 300-400 basis points as Andhra Pradesh, which accou...

Price spike in last-minute trades of Ruchi Soya on the final day of trading left many traders & FIIs with losses amounting to Rs 6 -8 a sha...

The BSE has identified as many as 2,264, or over 20% of its listed scrips, as illiquid based on trading pattern in the last quarter.

Oil prices rose above $53 in Asian trade today on hopes a global effort to lift the world economy out of recession would yield results.

Satyam Computer Services will be in focus after the fraud-hit company said it has received approval from SEBI to sell a 51 per cent stake i...

The healthcare major has roped in investment bank Credit Suisse as an advisor for a likely deal, according to sources close to the developm...

Tata Steel and SAIL failed to sustain the previous session’s robust gains, and ended up among the prominent losers in a lacklustre, but ste...

Stocks are likely to remain under pressure on Monday as the global credit crisis worsened.

Eyecare major Sankara Nethralaya is setting up a Rs 20-crore hospital at Mukundapur in Kolkata.

Corporate events this week

Several of the world’s top drugmakers may weigh acquiring Bristol-Myers Squibb after it fired its chief executive, although suitors seem un...